Ori-TIL-002

N/A

Report date: 2022/02/23 10:54:24

Base Information

Drug NameOri-TIL-002

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsUterine Cervical Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesOriCell Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsUterine Cervical Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A